Prokopiou, D.E.; Chillà , A.; Margheri, F.; Fibbi, G.; Laurenzana, A.; Efthimiadou, E.K.
Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation. Pharmaceutics 2024, 16, 527.
https://doi.org/10.3390/pharmaceutics16040527
AMA Style
Prokopiou DE, Chillà A, Margheri F, Fibbi G, Laurenzana A, Efthimiadou EK.
Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation. Pharmaceutics. 2024; 16(4):527.
https://doi.org/10.3390/pharmaceutics16040527
Chicago/Turabian Style
Prokopiou, Danai E., Anastasia Chillà , Francesca Margheri, Gabriella Fibbi, Anna Laurenzana, and Eleni K. Efthimiadou.
2024. "Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation" Pharmaceutics 16, no. 4: 527.
https://doi.org/10.3390/pharmaceutics16040527
APA Style
Prokopiou, D. E., Chillà , A., Margheri, F., Fibbi, G., Laurenzana, A., & Efthimiadou, E. K.
(2024). Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation. Pharmaceutics, 16(4), 527.
https://doi.org/10.3390/pharmaceutics16040527
